. 2019 Oct 10;19:142. doi: 10.1186/s12893-019-0595-4

Table 2.

Pathological results and location of metastasis after three operations

Hospital	Time	Clinical symptoms	Pathology	Immunohistochemistry	Indicator of progressive increase	Tumor metastasis
Local hospital	2015	A painless mass	Sweat gland carcinoma	CK5/6(+), CK-20(−), CEA(−), BCL-2(+, 2%), KI-67(2 + , 60%), EMA(++)	KI-67(+, 60%)	No metastasis
First Affiliated Hospital of Medical College of Zhejiang University	2017	A painless mass	malignant eccrine carcinoma	CK5/6(+), CK7(+), CK20(+), P63(−), MMG(−), S-100(−), Ki-67(+, 70%),G15(−), CD43(−), PAS(+)	Ki-67(+, 70%)	Local skull metastasis
First Affiliated Hospital of Medical College of Zhejiang University	2018	Mass with tenderness Headache Intracranial hypertension	malignant eccrine carcinoma	CK5/6(+), CK7(+), CK20(−), P63(−), MMG(−), S-100(−), Ki-67(+, > 60%),G15(−), CD43(−), GCDFP15(−)	Ki-67(++, > 60%)	Local skull metastasis Dura metastasis

Hospital

Time

Clinical symptoms

Pathology

Immunohistochemistry

Indicator of progressive increase

Tumor metastasis

Local hospital

2015

A painless mass

Sweat gland carcinoma

CK5/6(+), CK-20(−), CEA(−), BCL-2(+, 2%), KI-67(2 + , 60%), EMA(++)

KI-67(+, 60%)

No metastasis

First Affiliated Hospital of Medical College of Zhejiang University

2017

A painless mass

malignant eccrine carcinoma

CK5/6(+), CK7(+), CK20(+), P63(−), MMG(−), S-100(−), Ki-67(+, 70%),G15(−), CD43(−), PAS(+)

Ki-67(+, 70%)

Local skull metastasis

First Affiliated Hospital of Medical College of Zhejiang University

2018

Mass with tenderness

Headache

Intracranial hypertension

malignant eccrine carcinoma

CK5/6(+), CK7(+), CK20(−), P63(−), MMG(−), S-100(−), Ki-67(+, > 60%),G15(−), CD43(−), GCDFP15(−)

Ki-67(++, > 60%)

Local skull metastasis

Dura metastasis